Dariohealth Corp. · NASDAQ:DRIO
Dariohealth — Investor Presentation (February 2023)
26 slides from Dariohealth's investor presentation, Feb 6, 2023
Slide 1: DarioHealth Corp. - A Comprehensive, User-Centric Digital Health Platform
1 DARIOHEALTH CORP. Nasdaq | DRIO February 2023 A Comprehensive, User - Centric Digital Health Platform
Slide 2: Forward Looking Statement
01 Forward Looking Statement This presentation of DarioHealth Corp. (the Company ” ) and statements of our management or agents related thereto contain or may contain forward - looking statements within the meanin g of the Private Securities Litigation Reform Act of 1995 (the “ Act ” ). Statements w
Slide 3: Our Mission and Our Value
3 OUR MISSION We make it easy for people to care for their health, with continuous and connected support that anticipates needs, understands motivation, and simplifies behavior change to put better health and outcomes in everyone’s reach. 3 OUR VALUE Dario is a leader in the global digital Health ma
Slide 4: Significant TAM and Clinical Outcomes
Clinical Outcomes Significant TAM Total Addressable Market; M etabolic $ 108 B, MSK $ 90 B Behavior Health $ 9 B (*) Product Excellence $ 207 B With over 20 K reviews on Appstore. DTx Multi condition 4.9/5 Powerful Business Model Value - Based, Simple & Transparent, high Gross margin PEMPM busines
Slide 5: Chronic Conditions Remain Unsolved
5 5 https://onlinelibrary.wiley.com/doi/abs/ 10.1111 /j. 1746 - 1561.2006.00093 .x https://www.cdc.gov/chronicdisease/pdf/ 2009 - power - of - prevention.pdf https://www.rand.org/content/dam/rand/pubs/tools/TL 200 /TL 221 /RAND_TL 221 .pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC 5876976 / 147
Slide 6: TAM - Exceptional and Untapped $171B Opportunity
6 * Calculated as $ 60 PMPM for diabetes, $ 30 PMPM for Hypertension and $ 50 PMPM for MSK diabetesresearch.org |. sciencedaily.com |. who.int |. heart.org |. medscape.com TAM – Exceptional and Untapped $ 171 B opportunity in the U.S. alone. Of which less than 2 % is already penetrated.
Slide 7: Superior Economics, High-Value Partnerships, Profitable Growth
7 Superior Economics High - Value Partnerships Profitable Growth Differentiated Solution Market Necessity Our B 2 B transformation has driven Dario ’ s profitable growth and has already demonstrated demand for an integrated solution with self - insured employers and health plans Business Model Evolu
Slide 8: Expansion to B2B2C and Multi-Conditions Drives Growth
8 2016 2017 2018 2019 2020 2021 Diabetes Offering Hypertension Weight Management Launch Direct - to - Consumer Musculoskeletal Behavioral Health Total 100 Clients Expansion to B 2 B 2 C and Multi - Conditions Drives Exponential Growth Launch Business - to - Business First B 2 B client win 65,000 use
Slide 9: One Powerful Experience
9 Give your people better health outcomes, with engaging solutions that motivate lasting change. ONE POWERFUL EXPERIENCE
Slide 10: Member Has One Consolidated Experience
10 One journey One coaching program Metabolic Musculoskeletal Behavioral Health Fully Integrated Holistic User Centric Member has ONE Consolidated Experience
Slide 11: Dynamic and Adaptive Journeys
11 Dynamic and Adaptive Journeys
Slide 12: Outcomes, ROI and Engagement Validation
12 12 ROI ROI 3.4 X $ 2,376 PMPY Outcomes User Centric 1.4 % reduction in A 1 c 54% reduction in severe pain 248,000 users consumer DNA, D 2 C self - pay space 60 % reduction in hyperglycemic events Engagement 80 % retention year - over - year 4.9 / 5 Stars app store rating Validation Supported by O
Slide 13: Dario Covers 6 of Employers' Top Priorities in a Single Solution
13 Behavioral health Diabetes Financial well - being Nutrition / weight management Physical activity Cardiovascular health Musculoskeletal Cancer Family planning and support Social determinants of health Senior care None of the above 74% 49 % 48 % 40 % 39 % 28 % 26 % 23 % 14% 8 % 4 % 9 % And transfo
Slide 14: The Dario Advantage and Commercial Momentum
14 Good commercial momentum by Dario evidenced by 2022 doubling of contracts from 50 to 100 (*) K ey Employee survey findings The Dario Advantage Demand for digital health remains high with most employers planning on adding more solutions Dario covers all top digital health products employers are pl
Slide 15: Dario is Well Positioned To Win
15 15 Basic / No integration Technology / Scalable / Open - Partnership driven architecture Service Driven Full Best - of - suite/ consumer driven Number of Conditions Covered 5 or more 3 - 4 2 or less • Less than 2 % total market penetration • Most players try to solve single problem • None of the
Slide 16: Mature Partners Select Dario to Accelerate Digitalization
16 16 Strategic approach to partnership accelerates commercial adoption and enhances competitiveness Mature Partners Select Dario to Accelerate Digitalization
Slide 17: Partnerships: Demand Across Key Channels
17 17 + 78 Clients Fully insured Partner with self insured employers 3 Clients Medicare Reimbursement Accelerates provider revenue and value delivery 8 Clients Self insured Employers Consumer satisfaction and cost reduction 11 Clients Channel Partners Strategic Partners Employers Health Plans / Insu
Slide 18: Sanofi Strategic Agreement
18 • Multi - year , $ 30 million - dollar agreement, will help accelerate commercial adoption of Dario's full suite of digital therapeutics and drive the expansion of digital health solutions on the Dario platform. • Sanofi selected Dario to leverage its broad suite of digital therapeutics and its a
Slide 19: Dario's Multi Condition Compounding Economics
19 Single Condition Account Multi condition Account Example of an Employer with 10,000 Employees 8 % Eligible Enrollment Rate 35 % Up to ϰϬй Eligible $ 60 PEMPM $ 0.2 M per account per year Potential 6 X revenue on similar sales effort $ 89 PEMPM $ 1.2 M per account per year More Members per acc
Slide 20: Single vs. Multi Condition on Winning Accounts
20 20 0 10 20 30 40 50 60 70 80 90 100 2020 2021 2022 15 % 50 % 0 % Sign more Full suite accounts Single Vs. Multi Condition – on winning accounts
Slide 21: Contracts to Revenue and Gross Margin Trend
21 21 $ 0 $ 5,000 $ 10,000 $ 15 M $ 20 M $ 25 M $ 30 M $ 35 M $ 40 M $ 45 M Contracts to Revenue and Gross Margin Trend 2020 2021 2022 $ 3 M Contract value (ARR) $ 35 M Contract value (ARR) $ 6 5 M Contract value (ARR) B 2 C Revenue B 2 B Revenue 33 % Gross Margins * 39 % Gross Margins **~ 50 % Gros
Slide 22: Accounts to Users to Revenue
22 22 Accounts to Users to Revenue Signed accounts Partners network with access to accounts 2020 2021 2022 0 20 40 60 80 100 120 250 5,000 15,000 100 Accounts 54 Accounts 5 $ 3 M Contract value (ARR) $ 35 M Contract value (ARR) $ 6 5 M Contract value (ARR) Accounts Accounts Accounts
Slide 23: Capital Structure and Balance Sheet Snapshot
23 23 Stock Price $5.82 Shares Outstanding 25,761K Market Cap $150M Capital Structure Balance Sheet & Capitalization Snapshot Shares Outstanding 25,761K Preferred Shares 1,292K Prefunded Warrants 1,770K Warrants (Exercise Price: $4.05 - $12.00) 1,186K Warrants (Exercise Price: $5.20 - $25.00) 814K S
Slide 24: Experienced Executive Management Team
24 Rick Anderson President Erez Raphael CEO, Board Member Zvi Ben - David CFO Galya Gorodinsky SVP R&D and Delivery Solutions Omar Manejwala , M.D. Chief Medical Officer Experienced Executive Management Team Katy Guilfoile VP Client Success Josh Fischer SVP Operations and Compliance David Auslander
Slide 25: Board of Directors and Advisors
25 25 Dennis M. McGrath Chair of Audit - Board Member Adam Stern Board Member Yoav Shaked Chairman of the Board Hila Karah Board Member Yadin Shemer Advisory Board Allen Kamer Advisory Board Dennis Matheis Board Member Eric Milledge Chairman of the Scientific Advisory Board Marilyn Ritholz , PHD Sci
Slide 26: Thank You!
26 Thank You! 26